Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK, food effect, and safety study of AKP-009 in healthy Japanese men
jRCT2071230052Phase 1Active, not recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ludaterone acetate in benign prostatic hyperplasia (BPH) (13 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoints: Pharmacokinetic parameters of AKP-009, Food effect on pharmacokinetics and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
ludaterone acetate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCT2071230052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230052.